The fund projected a 2031 exit and the rate cap expires in 2029.

The dilution formula only appearing in an exhibit that wasn't attached is not an oversight, it's a choice.

I have never seen a capital call provision that was genuinely protective of LP interests when the dilution math was missing at signing. What happens instead is that the formula surfaces the first time it matters, which is exactly when the sponsor needs it to cut in their favor. By then you've already deployed your 180-day window and the tax clock is running whether you like the terms or not.

What's the asset class underneath this fund, multifamily, industrial, something else? Because the 2031 exit assumption reads very differently depending on whether the 2029 refi environment needs to carry a stabilized asset or a still-leasing-up one.

That gap is the actual deal structure, and the tax wrapper does not change the credit exposure underneath it.

Take a fund with a 20 million dollar bridge loan, a 2028 maturity, and a projected 2031 sale. The rate cap costs, say, 400k for two years and expires mid-2029. If the refi market in late 2028 prices the asset at a 7.5 cap and the business plan assumed a 5.5 exit cap, the loan-to-value on a new permanent loan drops hard enough that the fund either brings fresh equity or sells short of the appreciation window. The passive investor who reinvested a 500k gain to defer federal tax on that gain does defer it, the 2026 inclusion is unchanged, but the step-up in basis on the new appreciation only matters if there is net appreciation to exclude. A refi that requires a 2 million equity cure to close, funded by a capital call, dilutes the interest of anyone who does not fund, and that dilution formula sitting in an unattached exhibit is the mechanism that prices that outcome for each investor.

The question I would want answered before anything else is whether the rate cap is with the lender as a loan condition or held by the fund separately, because if it is a loan condition and it expires before maturity, the lender may have the right to declare a default or force a cash sweep that makes the extension option academic. What did the subscription documents say about who holds the cap agreement?

The rate cap is the expiration date the business plan was written around; the exit year is marketing.

The risk that tends to go unexamined is what the GP's waterfall looks like at a forced 2029 sale compared to a clean 2031 exit, because most promote structures are written so the GP still earns a meaningful carry at a compressed sales price, while the tax exclusion that made the deal attractive to LPs requires a hold the GP is no longer incentivized to fight for once a refi gets painful. Check whether the preferred return resets or steps up if the hold extends beyond the original 2031 target, because that is usually where you find whether the GP's interests stay aligned through a rough refinance or quietly diverge the moment extension fees start accumulating. Does the operating agreement give the GP discretion to call the sale, or does it require LP consent at a threshold that actually changes the outcome?

The scenario you described is the structural mismatch that gets papered over most often in QOF subscription materials, and you named the mechanism precisely. The tax benefit survives a forced sale only if the hold reaches ten years from the investment date. A 2029 liquidity event, forced by a maturing bridge with no viable refi, ends the hold two years short of that threshold and eliminates the appreciation exclusion entirely. The gain deferral on the original reinvested amount still applies through the 2026 recognition date under the rolling deferral structure in the new permanent regime, but the piece passive investors price most heavily, the exclusion on inside appreciation, requires the fund to actually get to year ten. A 2029 exit does not get there.

The missing exhibit is the detail I would press hardest. A capital call provision that exists in the operating agreement but whose dilution formula only appears in an unattached exhibit means the investor subscribed to a governance structure they cannot fully evaluate. That is a document integrity problem, separate from the economic risk. An attorney needs to opine on whether that exhibit is incorporated by reference in a way that binds the investor before the subscription is completed. I am not giving legal advice here, but the question requires one.

The refinancing assumption also needs pressure. If the bridge matures in late 2028 and the rate cap expires mid-2029, the sponsor is betting on a refi at a moment when they have lost their rate protection but before the loan is technically in default. That is the tightest window, not the widest, and the investor absorbs the outcome without having negotiated the loan terms, the cap structure, or the extension conditions.

The thing I would want to see is the lender's extension option language. A single six-month extension at the lender's discretion is meaningfully different from a borrower-controlled extension with defined conditions. Which is it in this fund's loan documents?